Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Change in the clinical development program for laquinimod
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta™, for Multiple Sclerosis
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Drug Safety Labeling Changes
The interplay between the intestinal microbiota and the brain.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Impact of MS during the critical window of brain development.
The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
BTG plc Close Period Update
Pregnancy outcomes in patients exposed to interferon beta-1b.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.

Pages